Christian Schirvel

Proposing the capabilities listed above to Companies looking for developing in Animal Health.

Actively involved in Expert Panel discussion with GLG, Third Bridge, AlphaSights, GuidePoint, ReferralKey, Experteer

Focusing on "One Health" … to the best of Humans, Animals, Environment, Nature!

Delivering value for the short-, mid- and long-term, aligned with Elanco's strategy

In-line with the Company Strategy, scout/identify opportunities, analyse their attractiveness, set-up a business/marketing plan, define a prospective P&L for the future potential product or technology, take part to the Due Diligence process, lead the evaluation/negotiation process and agree on the transaction terms, negotiate and agree on the Agreement with the partner, execute and manage the initial steps of the deal implementation. Obtain the approval of the required Lilly / Elanco's decision bodies. Propose and provide input to M&A opportunities; participate to the assessment. Responsibilities include from early-stage access to NCEs or technologies to fully developed products that Elanco could distribute through its M&S network, covering all market segments and type of products that are of interest to Elanco.

Parasiticides & Therapeutics (Cardiovascular, Dermatology/Allergy, Orthopedics/Pain/Inflammation, Antibiotics, Vaccines)

Delivering value for the short-, mid- and long-term, for the specified categories

In-line with the Company Category Strategy, identify opportunities, analyse their attractiveness, set-up a business/marketing plan, define a prospective P&L for the future potential product or technology, lead the Due Diligence process, negotiate and agree on terms, set-up the contract with the partner and execute the deal. Obtain the approval of the required decision bodies, that includes the Novartis Animal Health (NAH) BD&L Steering Committee, the NAH Investment board, or the Executive Committee of Novartis Group depending on the type and value of the deal. Propose and provide input to M&A opportunities assessments. Participate to the Strategic Bodies defining the needs of the Strategic Categories. Responsibilities include from early-stage access to NCEs / New Antigens or technologies to fully developed products that NAH could distribute through its M&S network.